Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial of Hypofractionated LocoRegional Radiotherapy in Breast Cancer and Lymphedema (RHEAL)

NCT04228991 is registered in ClinicalTrials.gov with Ontario Clinical Oncology Group (OCOG) as lead sponsor.

NCT NCT04228991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04228991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial of Hypofractionated LocoRegional Radiotherapy in Breast Cancer and Lymphedema (RHEAL)
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 10, 2021
Completion date
December 31, 2030
Enrollment
588 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, lymphedema, radiotherapy